Daiwa analyst Narumi Nakagiri downgraded Eli Lilly (LLY) to Neutral from Outperform with a $700 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s Stock Soars Amid Promising Trials
- Insider Moves: Microsoft, AMD, Boeing, AbbVie, Eli Lilly
- Moderately bullish activity in Eli Lilly with shares up 2.7%
- Trump Weekly: Trump weighs stake in Intel, candidates for Fed Chair
- Eli Lilly’s Promising Alzheimer’s Study: A Potential Game-Changer for Investors